218 related articles for article (PubMed ID: 32926754)
1. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study.
Seko Y; Yamaguchi K; Umemura A; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Moriguchi M; Okanoue T; Itoh Y
Hepatol Res; 2020 Dec; 50(12):1328-1336. PubMed ID: 32926754
[TBL] [Abstract][Full Text] [Related]
2. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.
Sugimoto R; Iwasa M; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
Front Med (Lausanne); 2023; 10():1073025. PubMed ID: 36824614
[TBL] [Abstract][Full Text] [Related]
3. Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
Takahashi Y; Seko Y; Yamaguchi K; Takeuchi K; Yano K; Kataoka S; Moriguchi M; Itoh Y
J Gastroenterol Hepatol; 2023 Oct; 38(10):1743-1749. PubMed ID: 37221601
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
[TBL] [Abstract][Full Text] [Related]
5. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study.
Shinozaki S; Tahara T; Lefor AK; Ogura M
Clin Exp Hepatol; 2021 Jun; 7(2):172-177. PubMed ID: 34295984
[TBL] [Abstract][Full Text] [Related]
6. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
Shinozaki S; Tahara T; Lefor AK; Ogura M
Clin Exp Hepatol; 2020 Sep; 6(3):270-274. PubMed ID: 33145434
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
[TBL] [Abstract][Full Text] [Related]
8. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.
Ikeda S; Sugihara T; Hoshino Y; Matsuki Y; Nagahara T; Okano JI; Kitao S; Fujioka Y; Yamamoto K; Isomoto H
Yonago Acta Med; 2020 Aug; 63(3):188-197. PubMed ID: 32884438
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
Yamada-Shimizu M; Tamaki N; Kurosaki M; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Ishido S; Nobusawa T; Matsumoto H; Keitoku T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
Intern Med; 2024 May; 63(9):1185-1190. PubMed ID: 37779070
[TBL] [Abstract][Full Text] [Related]
10. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203610
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
[TBL] [Abstract][Full Text] [Related]
12. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.
Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
Clin Exp Hepatol; 2022 Dec; 8(4):278-283. PubMed ID: 36683866
[TBL] [Abstract][Full Text] [Related]
13. Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD.
Iwadare T; Kimura T; Kunimoto H; Okumura T; Wakabayashi SI; Kobayashi H; Yamashita Y; Sugiura A; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2024; 15():1329294. PubMed ID: 38828415
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
[TBL] [Abstract][Full Text] [Related]
15. Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD.
Iwadare T; Kimura T; Kunimoto H; Tanaka N; Wakabayashi SI; Yamazaki T; Okumura T; Kobayashi H; Yamashita Y; Sugiura A; Joshita S; Umemura T
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359326
[TBL] [Abstract][Full Text] [Related]
16. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease.
Ishikawa T; Terai N; Igarashi T; Yamazaki S; Kobayashi T; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Clin Exp Hepatol; 2023 Jun; 9(2):172-178. PubMed ID: 37502434
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.
Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374110
[No Abstract] [Full Text] [Related]
18. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice.
Iitake C; Iitake K
J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783
[TBL] [Abstract][Full Text] [Related]
19. Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study.
Hatanaka T; Kakizaki S; Saito N; Nakano Y; Nakano S; Hazama Y; Yoshida S; Hachisu Y; Tanaka Y; Kashiwabara K; Yoshinaga T; Tojima H; Naganuma A; Uraoka T
Intern Med; 2021 Jul; 60(14):2167-2174. PubMed ID: 33612679
[TBL] [Abstract][Full Text] [Related]
20. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
